- Home
- MED vs MOLN Comparison
MED vs MOLN Comparison
Compare MED & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- MOLN
- Stock Information
- Founded
- MED 1980
- MOLN 2004
- Country
- MED United States
- MOLN Switzerland
- Employees
- MED N/A
- MOLN N/A
- Industry
- MED Packaged Foods
- MOLN
- Sector
- MED Consumer Staples
- MOLN
- Exchange
- MED Nasdaq
- MOLN Nasdaq
- Market Cap
- MED 156.7M
- MOLN 183.2M
- IPO Year
- MED N/A
- MOLN 2021
- Fundamental
- Price
- MED $13.47
- MOLN $3.88
- Analyst Decision
- MED Hold
- MOLN
- Analyst Count
- MED 1
- MOLN 0
- Target Price
- MED $16.50
- MOLN N/A
- AVG Volume (30 Days)
- MED 202.5K
- MOLN 4.4K
- Earning Date
- MED 04-28-2025
- MOLN 03-06-2025
- Dividend Yield
- MED N/A
- MOLN N/A
- EPS Growth
- MED N/A
- MOLN N/A
- EPS
- MED 0.19
- MOLN N/A
- Revenue
- MED $602,463,000.00
- MOLN $5,484,562.00
- Revenue This Year
- MED N/A
- MOLN N/A
- Revenue Next Year
- MED $2.10
- MOLN $528.57
- P/E Ratio
- MED $72.00
- MOLN N/A
- Revenue Growth
- MED N/A
- MOLN N/A
- 52 Week Low
- MED $13.47
- MOLN $3.32
- 52 Week High
- MED $38.56
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- MED 38.95
- MOLN 39.32
- Support Level
- MED $13.48
- MOLN $3.76
- Resistance Level
- MED $14.07
- MOLN $4.56
- Average True Range (ATR)
- MED 0.45
- MOLN 0.29
- MACD
- MED -0.01
- MOLN 0.02
- Stochastic Oscillator
- MED 0.72
- MOLN 11.87
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.